Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: debra vogt who wrote (56878)	8/22/1999 11:09:00 PM
From: kendall harmon	Read Replies (2) \| Respond to of 120523

Weekend Scans: EMLX, VIRS, VRTS, AREM, BTGC and NURM. Put them on watch list for this week. NURM earnings over about a week ago: biz.yahoo.com BTGC a new biotech play for me with a nice stochastics upturn on the chart: clearstation.com

To: debra vogt who wrote (56878)	8/22/1999 11:14:00 PM
From: kendall harmon	Respond to of 120523

BTGC a little bit more on this one: ISELIN, N.J.--(BUSINESS WIRE)--August 19, 1999--Bio-Technology General Corp. (NASDAQ:BTGC - news) announced that it was honored at the New Jersey Technology Fast 50 awards in Woodbridge, New Jersey, on August 18, 1999. The award was presented to the fifty fastest growing New Jersey based technology companies measured by percentage revenue growth over the five-year period between 1994 and 1998. BTG was awarded this honor for the fifth consecutive year, ranking 36th this time with five year growth of 341%. The fifty companies to achieve recognition consisted of 8 biomedical companies, 26 software/IT companies, 6 electronics/manufacturing companies, and 10 telecommunications companies. Sim Fass, BTG's Chairman and Chief Executive Officer, stated: ''Each year for the past five years we have demonstrated our ability to sustain our commercial growth, so this recognition once again is most welcome. We look forward to continuing to grow as our current product sales are maximized and new products in development come to market.'' Bio-Technology General Corp., a leading biopharmaceutical company, develops, manufactures and markets genetically engineered and other products for human health care. The Company's products are marketed in over thirty countries worldwide. Product sales and revenues in 1998 were $68.2 and $76.9, respectively.